Cargando…

Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis

OBJECTIVE: To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis. METHODS: Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Lib...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Kun, Ma, Jianling, Wang, Liangmin, Li, Niuniu, Dong, Shangjuan, Shi, Liqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040417/
https://www.ncbi.nlm.nih.gov/pubmed/32104189
http://dx.doi.org/10.1155/2020/1752387
_version_ 1783500984399429632
author Ji, Kun
Ma, Jianling
Wang, Liangmin
Li, Niuniu
Dong, Shangjuan
Shi, Liqing
author_facet Ji, Kun
Ma, Jianling
Wang, Liangmin
Li, Niuniu
Dong, Shangjuan
Shi, Liqing
author_sort Ji, Kun
collection PubMed
description OBJECTIVE: To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis. METHODS: Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Library, ClinicalTrials, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chin VIP Information (VIP), and Chinese Biomedical Database (CBM) until December 2018. Standard mean difference (SMD) and 95% CI were calculated for the measurements related to lung function (FEV1/FVC, FVC%, FEV1%, TLC%, DLCO% or DLCO, and VC%) and other parameters (PO(2), 6MWD, and SGRQ) when comparing TCM treatment to the control group. Relative risk (RR) and 95% CI of adverse events (AEs) were calculated to assess the safety of TCM. RESULTS: A total of 40 RCTs comparing TCM to western medicine (WM) and involving 3194 IPF patients were eligible for the meta-analysis. The pooled results showed that TCM treatment improved significantly PO(2) (SMD = 0.80, 95% CI 0.54 to 1.06, p < 0.001), FEV1% (SMD = 0.57, 95% CI 0.42 to 0.71, p < 0.001), DLCO% (SMD = 0.38, 95% CI 0.28 to 0.48, p < 0.001), 6MWD (SMD = 0.70, 95% CI 0.56 to 0.84, p < 0.001) and other measurements and reduced SGRQ scores (SMD = −0.51, 95% CI −0.70 to −0.22, p < 0.001). Subgroup analysis of different study durations (3 months, ≥ 6 months) and comparison models (TCM vs. WM, TCM + WM vs. WM or TCM vs. placebo) showed similar results. No significant difference of risk of AEs was observed between both groups (RR = 0.66, 95% CI: 0.27–1.60, p=0.352). There was no obvious publication bias, and the pooled results were stable according to sensitivity analysis. CONCLUSION: To the best of our knowledge, the present study had the largest sample size. Our results indicated that TCM treatment may help provide benefit to the lung function, exercise capacity, and quality of life of IPF patients, alone or combined with WM, when compared to WM. More rigorous RCTs were needed in the future.
format Online
Article
Text
id pubmed-7040417
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-70404172020-02-26 Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis Ji, Kun Ma, Jianling Wang, Liangmin Li, Niuniu Dong, Shangjuan Shi, Liqing Evid Based Complement Alternat Med Research Article OBJECTIVE: To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis. METHODS: Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Library, ClinicalTrials, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chin VIP Information (VIP), and Chinese Biomedical Database (CBM) until December 2018. Standard mean difference (SMD) and 95% CI were calculated for the measurements related to lung function (FEV1/FVC, FVC%, FEV1%, TLC%, DLCO% or DLCO, and VC%) and other parameters (PO(2), 6MWD, and SGRQ) when comparing TCM treatment to the control group. Relative risk (RR) and 95% CI of adverse events (AEs) were calculated to assess the safety of TCM. RESULTS: A total of 40 RCTs comparing TCM to western medicine (WM) and involving 3194 IPF patients were eligible for the meta-analysis. The pooled results showed that TCM treatment improved significantly PO(2) (SMD = 0.80, 95% CI 0.54 to 1.06, p < 0.001), FEV1% (SMD = 0.57, 95% CI 0.42 to 0.71, p < 0.001), DLCO% (SMD = 0.38, 95% CI 0.28 to 0.48, p < 0.001), 6MWD (SMD = 0.70, 95% CI 0.56 to 0.84, p < 0.001) and other measurements and reduced SGRQ scores (SMD = −0.51, 95% CI −0.70 to −0.22, p < 0.001). Subgroup analysis of different study durations (3 months, ≥ 6 months) and comparison models (TCM vs. WM, TCM + WM vs. WM or TCM vs. placebo) showed similar results. No significant difference of risk of AEs was observed between both groups (RR = 0.66, 95% CI: 0.27–1.60, p=0.352). There was no obvious publication bias, and the pooled results were stable according to sensitivity analysis. CONCLUSION: To the best of our knowledge, the present study had the largest sample size. Our results indicated that TCM treatment may help provide benefit to the lung function, exercise capacity, and quality of life of IPF patients, alone or combined with WM, when compared to WM. More rigorous RCTs were needed in the future. Hindawi 2020-02-13 /pmc/articles/PMC7040417/ /pubmed/32104189 http://dx.doi.org/10.1155/2020/1752387 Text en Copyright © 2020 Kun Ji et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ji, Kun
Ma, Jianling
Wang, Liangmin
Li, Niuniu
Dong, Shangjuan
Shi, Liqing
Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis
title Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis
title_full Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis
title_fullStr Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis
title_full_unstemmed Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis
title_short Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis
title_sort efficacy and safety of traditional chinese medicine in idiopathic pulmonary fibrosis: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040417/
https://www.ncbi.nlm.nih.gov/pubmed/32104189
http://dx.doi.org/10.1155/2020/1752387
work_keys_str_mv AT jikun efficacyandsafetyoftraditionalchinesemedicineinidiopathicpulmonaryfibrosisametaanalysis
AT majianling efficacyandsafetyoftraditionalchinesemedicineinidiopathicpulmonaryfibrosisametaanalysis
AT wangliangmin efficacyandsafetyoftraditionalchinesemedicineinidiopathicpulmonaryfibrosisametaanalysis
AT liniuniu efficacyandsafetyoftraditionalchinesemedicineinidiopathicpulmonaryfibrosisametaanalysis
AT dongshangjuan efficacyandsafetyoftraditionalchinesemedicineinidiopathicpulmonaryfibrosisametaanalysis
AT shiliqing efficacyandsafetyoftraditionalchinesemedicineinidiopathicpulmonaryfibrosisametaanalysis